Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality in adults, but there is still no acknowledged biomarker for its prognostic evaluation. Our previous proteomic data had demonstrated the dysregulation of some lipid metabolism enzymes in clear cell RCC (ccRCC). In the present study, we elucidated the expression of two lipid metabolism enzymes, hydroxyl-coenzyme A dehydrogenase, alpha subunit (HADHA) and acetyl-coenzyme A acetyltransferase 2 (ACAT2), using Western blotting analysis, then assessed the prognostic potential of HADHA and ACAT2 using immunohistochemistry (IHC) on a tissue microarray of 145 ccRCC tissues. HADHA and ACAT2 were downregulated in ccRCC (P < 0.05); further IHC analysis revealed that HADHA expression was significantly associated with tumor grade, stage, size, metastasis, and cancer-specific survival (P = 0.004, P < 0.001, P < 0.001, P = 0.049, P < 0.001, respectively) and ACAT2 expression was significantly associated with tumor stage, size, and cancer-specific survival (P < 0.001, P = 0.001, P < 0.001, respectively). In addition, a strong correlation was found between HADHA and ACAT2 expression (R = 0.655, P < 0.001). Further univariate survival analysis demonstrated that high stage, big tumor size, metastasis, and HADHA and ACAT2 down-expression were associated with poorer prognosis on cancer-specific survival (P = 0.007, P = 0.005, P = 0.006, P < 0.001, P = 0.001, respectively), and multivariate analysis revealed that HADHA, stage, and metastasis were identified as independent prognostic factors for cancer-specific survival in patients with ccRCC (P = 0.018, P = 0.046, P = 0.001, respectively). Collectively, these findings indicated that HADHA could serve as a promising prognostic marker in ccRCC, which indicated lipid metabolism abnormality might be involved in ccRCC tumorigenesis.
This is a preview of subscription content, log in to check access.
This study was supported in part by the grants from the Shandong Key Research and Development Project (No. 2015GSF118055 and 2012YD18049), the Natural Science Foundation of Shandong Province (No. 2014ZRB14513 and 2014ZRB14081), and the Medicine and Healthcare Technology Development Project of Shandong Province (No. 2014WS0341).
Compliance with ethical standards
All procedures were consistent with the National Institutes of Health Guide and approved by the institutional board with patients’ written consent. This study was evaluated and approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University.
Conflicts of interest
Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, et al. Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE. Mol BioSyst. 2012;8(4):1040–51. doi:10.1039/c2mb05390j.CrossRefPubMedGoogle Scholar
Zhao Z, Wu F, Ding S, Sun L, Liu Z, Ding K, et al. Label-free quantitative proteomic analysis reveals potential biomarkers and pathways in renal cell carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36(2):939–51. doi:10.1007/s13277-014-2694-2.CrossRefGoogle Scholar
White NM, Masui O, Desouza LV, Krakovska O, Metias S, Romaschin AD, et al. Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget. 2014;5(2):506–18.CrossRefPubMedPubMedCentralGoogle Scholar
Tanaka M, Masaki Y, Tanaka K, Miyazaki M, Kato M, Sugimoto R, et al. Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol Med Rep. 2013;7(2):365–70. doi:10.3892/mmr.2012.1201.PubMedGoogle Scholar
Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol WJG. 2014;20(9):2279–303. doi:10.3748/wjg.v20.i9.2279.CrossRefPubMedGoogle Scholar
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, et al. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN projectdagger. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015. doi:10.1093/annonc/mdv380.Google Scholar
Orii KE, Orii KO, Souri M, Orii T, Kondo N, Hashimoto T, et al. Genes for the human mitochondrial trifunctional protein alpha- and beta-subunits are divergently transcribed from a common promoter region. J Biol Chem. 1999;274(12):8077–84.CrossRefPubMedGoogle Scholar
Kageyama T, Nagashio R, Ryuge S, Matsumoto T, Iyoda A, Satoh Y, et al. HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer. Asian Pac J Cancer Prevent APJCP. 2011;12(12):3457–63.Google Scholar
Xu CZ, Shi RJ, Chen D, Sun YY, Wu QW, Wang T, et al. Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell. Int J Clin Exp Pathol. 2013;6(12):2745–56.PubMedPubMedCentralGoogle Scholar
Sadeghi RN, Karami-Tehrani F, Salami S. Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36(4):2893–905. doi:10.1007/s13277-014-2919-4.CrossRefGoogle Scholar
Sanchez-Martinez R, Cruz-Gil S, Gomez de Cedron M, Alvarez-Fernandez M, Vargas T, Molina S et al. A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy. Oncotarget. 2015.Google Scholar